Digital Biomarkers Market Size, Share, Opportunities, And Trends By Type (Mobile Health Apps, Wearable Devices, Others), By Therapeutic Area (Cardiovascular Disorders, Neurological Disorders, Respiratory Disorders, Metabolic Disorders, Others), By End User (Pharmaceutical Companies, Healthcare Providers, Research Organizations, Others), And By Geography - Forecasts From 2023 To 2028

The digital biomarkers market is projected to grow at a CAGR of 31.58% during the forecast period to reach US$22.540 billion by 2030 from US$5.714 billion in 2025.

Digital biomarkers measure physiological or behavioural data of patients using digital devices like wearables, smartphones and sensors, enabling real-time monitoring of health, disease progression and treatment outcomes. It is significantly transforming healthcare as it is non-invasive and offers real-time monitoring of health. Digital biomarkers are poised to revolutionize mainstream drug development and amplify our understanding of treatment efficacy. Thus, digital biomarkers are changing the future of the market of personalized healthcare market and are transforming the lives of patients. 

The market is anticipated to grow at a significant rate due to the increasing adoption of digital health technologies for real-time health monitoring. As the adoption of digital technologies is growing, it is also increasing utilization of digital biomarkers in chronic disease management, clinical trials and personalized healthcare for quantifying data on physiological and behavioural metrics, which is one of the key factors propelling the market to grow. 

Furthermore, the increasing adoption of wearables and smartphones is propelling the market to grow. As there is increasing innovation in AI, machine learning and sensor technologies, the digital biomarkers are offering improved accuracy and are also improving their scope of application, giving a boost to the market growth. 

The market is also witnessing key developments, such as increasing advancements in new-generation wearables now include multi-parameter sensors and smartphone-based digital biomarkers. There is an increasing partnership among companies. For instance, Biofourmis announced four new agreements with top pharmaceutical companies, driven by Biofourmis’ proven leadership and expertise in digital biomarker development. It spans across the United States, Europe, Asia-Pacific, and the Middle East.

Digital Biomarkers Market Overview & Scope

The Digital biomarkers market is segmented by:

• Type: The digital biomarkers market is segmented by type into mobile health apps, wearable devices, and others. Among these, wearable devices dominate the market due to their growing integration with healthcare monitoring systems.
• Therapeutic Area: The market is also segmented by therapeutic area into cardiovascular disorders, neurological disorders, respiratory disorders, metabolic disorders, and others. The cardiovascular segment holds the largest share, driven by the high global prevalence of heart-related diseases, which need digital biomarkers as they offer real-time monitoring of vital signs.
• End-User: Based on end-user, the digital biomarkers market is segmented into pharmaceutical companies, healthcare providers, research organizations, and others. Pharmaceutical companies form a major end-user group as they use digital biomarkers in drug development, clinical trials, and post-market surveillance for cutting down cost and improving trial outcomes. The digital biomarker is anticipated to change the drug development pathway in the coming years.
• Region: The digital biomarkers market, by geography, is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. Each region plays a distinct role in the market's development. The North America will hold a considerable market share which is attributable to the region’s sophisticated healthcare infrastructure and significant investments in digital health technology. Likewise, the presence of significant pharmaceutical conglomerates and technological giants in the region encourages collaboration and innovation in the development of digital biomarkers. Furthermore, digital biomarkers market growth is fuelled by favorable government initiatives and policies. Lastly, North America's dominance in the digital biomarkers market share is aided by the region's rapid adoption of wearable devices, mobile health applications, and remote patient monitoring solutions.

________________________________________

Top Trends Shaping the Digital Biomarkers Market

1. Increasing Adoption of Wearable Devices and Mobile Health Applications

• The digital biomarkers market is moving forward as wearable devices and mobile health apps are becoming more and more popular. Users can use these technologies to measure vital signs, collect data on a variety of health metrics, and keep track of their health in an easy-to-use manner. Digital biomarkers can now be created and used in a more personalized and precise manner thanks to the growing use of wearables and mobile applications.

2. Expansion of Digital Infrastructure and Connectivity

• The expansion of digital infrastructure and connectivity is necessary for the digital biomarkers market to expand. Digital biomarkers can now be seamlessly integrated into healthcare systems owing to the widespread adoption of the internet, advancements in telecommunications, and the introduction of 5G networks. All of these factors have increased access to data collection, storage, and analysis. 

________________________________________

Digital biomarkers Market Growth Drivers

Drivers:

• Rising Prevalence of Chronic Diseases: A significant driver for the market is the rising prevalence of chronic diseases like cardiovascular diseases (CVD), diabetes, and neurological disorders, which is driving demand for digital biomarkers. The rising prevalence of diseases is illustrated by data from the World Health Organization. Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. The NCD portal highlights that NCDs account for 74% of all deaths. 
• Growth in Remote Patient Monitoring: The digital biomarkers market is experiencing significant expansion as a result of the rising demand for remote patient monitoring solutions. Healthcare professionals can remotely monitor their patient's health status, collect real-time data, and identify potential issues with remote patient monitoring. This demand is being driven by the need for healthcare delivery that is both efficient and cost-effective, particularly for patients who have chronic conditions or who require continuous monitoring. Thus, the growth in remote patient monitoring is fueling the digital biomarkers market as it directly supports digital biomarkers by increasing the availability of devices such as smartwatches, glucose monitors that collect biomarker data. 

Also, as chronic diseases are rising, there is an increasing demand for continuous monitoring, supporting the digital biomarker market. As healthcare is shifting toward home-based and virtual care, the digital biomarkers market is growing significantly, driven by the integration of digital biomarkers into home-based and virtual care platforms. As per a report, there is an increasing home-care concept after the introduction of the Centers for Medicare & Medicaid Services' (CMS) Acute Hospital Care at Home program.   As per a survey by the AARP (American Association of Retired Persons) 2021 "Home and Community Preferences", there is a higher preference for desire to age in Place. 77% of adults aged 50+ want to remain in their homes as they age. It highlights the increasing demand for home-based healthcare or remote patient monitoring, driving the market. 

• Rising Adoption of Smartwatches: Smartwatches serve as continuous, real-time health monitoring devices, which makes them essential in the market for digital biomarkers.  These wearable gadgets have sensors built in that may gather a variety of physiological data, including body temperature, physical activity, blood oxygen levels (SpO2), heart rate, sleep patterns, and even stress markers.  The data is evaluated to produce digital biomarkers, which are objective, measurable physiological and behavioral data points that are gathered and assessed using digital devices to show results connected to health. Hence global sales of smartwatches have increased significantly in recent years. The smartwatch industry's earnings increased from about US $12.67 billion in 2017 to US $44.94 billion by 2023, and by 2028, they are expected to reach US $62.46 billion according to data from the National Library of Medicine.

________________________________________

Digital Biomarkers Market Regional Analysis

• North America: North American market is expected to account for a notable share in terms of revenue and is anticipated to continue its dominance over the market throughout the forecast period. The convergence of cutting-edge technologies, changing healthcare paradigms, and the growing emphasis on precision medicine and preventative care are driving the dynamic and steady expansion of the digital biomarkers market in the United States. Digital biomarkers, which are objective, measurable physiological and behavioral data gathered by digital technologies like wearable sensors, smartphone apps, and connected medical devices, are revolutionizing the diagnosis, tracking, and treatment of medical diseases. The need for non-invasive, real-time monitoring technologies is growing rapidly in the United States, a nation with a high prevalence of chronic diseases like diabetes, cardiovascular ailments, neurodegenerative conditions, and mental health issues.

Pharmaceutical companies are also becoming more interested in employing digital biomarkers in clinical trials to increase patient engagement and retention, raise endpoint measurement, and save costs. The market is being driven forward by robust investment trends, supportive governmental frameworks, and a social movement toward proactive, data-driven healthcare, even though obstacles like data protection, standardization, and clinical validation still exist. A future where continuous, personalized health data leads to better outcomes and more effective care delivery is supported by the digital biomarkers market, which is set to become a key component of next-generation medical innovation as the US healthcare ecosystem continues to embrace digital transformation.

________________________________________

Digital biomarkers Market Key Developments

• Company Expansion: In 2024, The world's top health technology company for sleep, breathing, and in-home care, ResMed, announced the AirTouchTM N30i, a ResMed first in CPAP mask innovation. The AirTouch N30i, a fabric-wrapped frame with a soft, breathable, and moisture-wicking design for maximum comfort in a tube-up design, is made to give users a natural and comfortable sleeping experience.

________________________________________

Digital Biomarkers Market Segmentation: 

By Type

• Mobile Health Apps
• Wearable Devices
• Others

By Therapeutic Area

• Cardiovascular Disorders
• Neurological Disorders
• Respiratory Disorders
• Metabolic Disorders
• Others   

By End-User

• Pharmaceutical Companies
• Healthcare Providers
• Research Organizations
• Others    

By Region

• North America
  • USA
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL ADVANCEMENTS

5. DIGITAL BIOMARKERS MARKET BY TYPE

5.1. Introduction

5.2. Mobile Health Apps

5.3. Wearable Devices

5.4. Others

6. DIGITAL BIOMARKERS MARKET BY THERAPEUTIC AREA

6.1. Introduction

6.2. Cardiovascular Disorders

6.3. Neurological Disorders

6.4. Respiratory Disorders

6.5. Metabolic Disorders

6.6. Others   

7. DIGITAL BIOMARKERS MARKET BY END-USER

7.1. Introduction

7.2. Pharmaceutical Companies

7.3. Healthcare Providers

7.4. Research Organizations

7.5. Others    

8. DIGITAL BIOMARKERS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type

8.2.2. By Therapeutic Area

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Type

8.3.2. By Therapeutic Area

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Type

8.4.2. By Therapeutic Area

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Type

8.5.2. By Therapeutic Area

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Type

8.6.2. By Therapeutic Area

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Biofourmis Inc. 

10.2. Evidation Health Inc. 

10.3. ResMed Inc. 

10.4. Verily Life Science LLC 

10.5. Empatica Inc. 

10.6. Koneska Health Inc. 

10.7. Biobeat Technologies Ltd. 

10.8. ActiGraph LLC 

10.9. Huma Therapeutics Ltd. 

10.10. Neurometrix Inc. 

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Biofourmis Inc. 

Evidation Health Inc. 

ResMed Inc. 

Verily Life Science LLC 

Empatica Inc. 

Koneska Health Inc. 

Biobeat Technologies Ltd. 

ActiGraph LLC 

Huma Therapeutics Ltd. 

Neurometrix Inc.